Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients

Carlo Garufi, Barbara Vanni, Anna Maria Aschelter, Albina Rita Zappalà, Emilio Bria, Cecila Nisticò, Isabella Sperduti, Francesco Cognetti, Edmondo Terzoli

Research output: Contribution to journalArticle

Abstract

In this study, a randomised phase II trial explored the effects of 6-h chronomodulated CPT-11 infusion in advanced colorectal cancer patients. Sixty-eight pre-treated patients were randomly assigned to CPT-11 administered at 180 mg/m2 on day 1, by 1-h infusion (Arm A) or 6-h sinusoidal infusion with peak timing at 5:00 a.m. (Arm B). All patients also received chronomodulated folinic acid/5-fluorouracil (FA/5-FU). Patients in Arm B obtained a 25.7% response rate for 7.0 months duration, a progression-free survival for 8.0 months and a median survival of 28 months. The same data in Arm A were 18.2%, 4.5, 6.0 and 18 months, respectively. No differences in drugs dose-intensity or increased toxicity with prolonged chronomodulated infusion were detected. Major grade 3-4 toxicity was diarrhoea: 10 patients in Arm A and 13 in Arm B. In conclusion, this study has shown that chronomodulated infusion of CPT-11 and FA/5-FU is safe, active and can be integrated with oxaliplatin (EORTC 05011) for the treatment of advanced colorectal cancer.

Original languageEnglish
Pages (from-to)608-616
Number of pages9
JournalEuropean Journal of Cancer
Volume42
Issue number5
DOIs
Publication statusPublished - Mar 2006

Fingerprint

irinotecan
Leucovorin
Fluorouracil
Colorectal Neoplasms
oxaliplatin
Disease-Free Survival
Diarrhea

Keywords

  • 5-Fluorouracil
  • Chronomodulation
  • Colorectal cancer
  • Irinotecan

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. / Garufi, Carlo; Vanni, Barbara; Aschelter, Anna Maria; Zappalà, Albina Rita; Bria, Emilio; Nisticò, Cecila; Sperduti, Isabella; Cognetti, Francesco; Terzoli, Edmondo.

In: European Journal of Cancer, Vol. 42, No. 5, 03.2006, p. 608-616.

Research output: Contribution to journalArticle

Garufi, Carlo ; Vanni, Barbara ; Aschelter, Anna Maria ; Zappalà, Albina Rita ; Bria, Emilio ; Nisticò, Cecila ; Sperduti, Isabella ; Cognetti, Francesco ; Terzoli, Edmondo. / Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients. In: European Journal of Cancer. 2006 ; Vol. 42, No. 5. pp. 608-616.
@article{23fcf177adf648ab8635610719591cdf,
title = "Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients",
abstract = "In this study, a randomised phase II trial explored the effects of 6-h chronomodulated CPT-11 infusion in advanced colorectal cancer patients. Sixty-eight pre-treated patients were randomly assigned to CPT-11 administered at 180 mg/m2 on day 1, by 1-h infusion (Arm A) or 6-h sinusoidal infusion with peak timing at 5:00 a.m. (Arm B). All patients also received chronomodulated folinic acid/5-fluorouracil (FA/5-FU). Patients in Arm B obtained a 25.7{\%} response rate for 7.0 months duration, a progression-free survival for 8.0 months and a median survival of 28 months. The same data in Arm A were 18.2{\%}, 4.5, 6.0 and 18 months, respectively. No differences in drugs dose-intensity or increased toxicity with prolonged chronomodulated infusion were detected. Major grade 3-4 toxicity was diarrhoea: 10 patients in Arm A and 13 in Arm B. In conclusion, this study has shown that chronomodulated infusion of CPT-11 and FA/5-FU is safe, active and can be integrated with oxaliplatin (EORTC 05011) for the treatment of advanced colorectal cancer.",
keywords = "5-Fluorouracil, Chronomodulation, Colorectal cancer, Irinotecan",
author = "Carlo Garufi and Barbara Vanni and Aschelter, {Anna Maria} and Zappal{\`a}, {Albina Rita} and Emilio Bria and Cecila Nistic{\`o} and Isabella Sperduti and Francesco Cognetti and Edmondo Terzoli",
year = "2006",
month = "3",
doi = "10.1016/j.ejca.2005.03.012",
language = "English",
volume = "42",
pages = "608--616",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "5",

}

TY - JOUR

T1 - Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients

AU - Garufi, Carlo

AU - Vanni, Barbara

AU - Aschelter, Anna Maria

AU - Zappalà, Albina Rita

AU - Bria, Emilio

AU - Nisticò, Cecila

AU - Sperduti, Isabella

AU - Cognetti, Francesco

AU - Terzoli, Edmondo

PY - 2006/3

Y1 - 2006/3

N2 - In this study, a randomised phase II trial explored the effects of 6-h chronomodulated CPT-11 infusion in advanced colorectal cancer patients. Sixty-eight pre-treated patients were randomly assigned to CPT-11 administered at 180 mg/m2 on day 1, by 1-h infusion (Arm A) or 6-h sinusoidal infusion with peak timing at 5:00 a.m. (Arm B). All patients also received chronomodulated folinic acid/5-fluorouracil (FA/5-FU). Patients in Arm B obtained a 25.7% response rate for 7.0 months duration, a progression-free survival for 8.0 months and a median survival of 28 months. The same data in Arm A were 18.2%, 4.5, 6.0 and 18 months, respectively. No differences in drugs dose-intensity or increased toxicity with prolonged chronomodulated infusion were detected. Major grade 3-4 toxicity was diarrhoea: 10 patients in Arm A and 13 in Arm B. In conclusion, this study has shown that chronomodulated infusion of CPT-11 and FA/5-FU is safe, active and can be integrated with oxaliplatin (EORTC 05011) for the treatment of advanced colorectal cancer.

AB - In this study, a randomised phase II trial explored the effects of 6-h chronomodulated CPT-11 infusion in advanced colorectal cancer patients. Sixty-eight pre-treated patients were randomly assigned to CPT-11 administered at 180 mg/m2 on day 1, by 1-h infusion (Arm A) or 6-h sinusoidal infusion with peak timing at 5:00 a.m. (Arm B). All patients also received chronomodulated folinic acid/5-fluorouracil (FA/5-FU). Patients in Arm B obtained a 25.7% response rate for 7.0 months duration, a progression-free survival for 8.0 months and a median survival of 28 months. The same data in Arm A were 18.2%, 4.5, 6.0 and 18 months, respectively. No differences in drugs dose-intensity or increased toxicity with prolonged chronomodulated infusion were detected. Major grade 3-4 toxicity was diarrhoea: 10 patients in Arm A and 13 in Arm B. In conclusion, this study has shown that chronomodulated infusion of CPT-11 and FA/5-FU is safe, active and can be integrated with oxaliplatin (EORTC 05011) for the treatment of advanced colorectal cancer.

KW - 5-Fluorouracil

KW - Chronomodulation

KW - Colorectal cancer

KW - Irinotecan

UR - http://www.scopus.com/inward/record.url?scp=33644747251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644747251&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.03.012

DO - 10.1016/j.ejca.2005.03.012

M3 - Article

C2 - 16246545

AN - SCOPUS:33644747251

VL - 42

SP - 608

EP - 616

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 5

ER -